345 related articles for article (PubMed ID: 33554807)
21. Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor.
Wang Y; Liu A; Xu T; Yin J; Chen W
Clin Med Insights Oncol; 2022; 16():11795549221109500. PubMed ID: 35875418
[TBL] [Abstract][Full Text] [Related]
22. Glutathione combined with mecobalamin in the treatment of chemotherapy-induced peripheral neuropathy in multiple myeloma: a retrospective clinical study.
Huang H; Zhao M; Liu X; Song J; Liu L; Liu Y; Xiang P; Wang Y; Fang B
Ann Palliat Med; 2021 Dec; 10(12):12335-12346. PubMed ID: 35016427
[TBL] [Abstract][Full Text] [Related]
23. Identification of patients at high risk of secondary extramedullary multiple myeloma development.
Stork M; Sevcikova S; Minarik J; Krhovska P; Radocha J; Pospisilova L; Brozova L; Jarkovsky J; Spicka I; Straub J; Pavlicek P; Jungova A; Jelinek T; Sandecka V; Maisnar V; Hajek R; Pour L
Br J Haematol; 2022 Feb; 196(4):954-962. PubMed ID: 34726261
[TBL] [Abstract][Full Text] [Related]
24. Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study.
Gao S; Li Q; Dong F; Yang P; Chen Y; Wang J; Wang Y; Jing H
Leuk Res; 2022 Apr; 115():106793. PubMed ID: 35248783
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy and Influencing Factors of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Retrospective Analysis].
Zhang BL; Zhou J; Zhang GL; Gui RR; Lin QD; Zu YL; Yu FC; Zhao HF; Li Z; Wang J; Fu YW; Zhang LN; Zhou H; Fang BJ; Song YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1414-1419. PubMed ID: 30295260
[TBL] [Abstract][Full Text] [Related]
26. [Expression of CD45 in newly diagnosed multiple myeloma and the relationship with prognosis].
Shi J; Zhu ZM; Sun K; Lei PC; Liu ZW; Guo JM; Yang J; Zang YZ; Zhang Y
Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):744-749. PubMed ID: 31648475
[No Abstract] [Full Text] [Related]
27. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
Varga C; Xie W; Laubach J; Ghobrial IM; O'Donnell EK; Weinstock M; Paba-Prada C; Warren D; Maglio ME; Schlossman R; Munshi NC; Raje N; Weller E; Anderson KC; Mitsiades CS; Richardson PG
Br J Haematol; 2015 Jun; 169(6):843-50. PubMed ID: 26032514
[TBL] [Abstract][Full Text] [Related]
28. [Bortezomib-based chemotherapy for patients with multiple myeloma: a single center experience].
Liang Z; Ren H; Cen X; Li Y; Wang L; Ou J; Dong Y; Yin Y; Wang W; Liu W; Wang Q; Qiu Z; Wang M; Xu W; Sun Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):225-30. PubMed ID: 24666489
[TBL] [Abstract][Full Text] [Related]
29. [Clinical Features and Prognostic Factors of Patients with Multiple Myeloma].
Gong YY; Yan XS; Wang YM; Pan JL; Zhai YY; Chen SN; Liu DD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):772-780. PubMed ID: 34105471
[TBL] [Abstract][Full Text] [Related]
30. [Predictive Value of Pre-treatment Serum Uric Acid Level for Prognosis in Newly Diagnosed Patients with Multiple Myeloma].
Xu SQ; Zhao P; Wang ZH; Deng H; Zhang L; Wei J; Zou XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1216-1223. PubMed ID: 34362505
[TBL] [Abstract][Full Text] [Related]
31. Adverse prognostic impact of bone marrow microvessel density in multiple myeloma.
Lee N; Lee H; Moon SY; Sohn JY; Hwang SM; Yoon OJ; Youn HS; Eom HS; Kong SY
Ann Lab Med; 2015 Nov; 35(6):563-9. PubMed ID: 26354343
[TBL] [Abstract][Full Text] [Related]
32. [Clinical features and outcome analyses of newly-diagnosed multiple myeloma with extramedullary involvements].
Zhang YZ; Zhi YQ; Wang YF; Yu Y; Zhao ZG; Wang XF; Zhai QL; Sun BC
Zhonghua Yi Xue Za Zhi; 2012 Sep; 92(34):2415-8. PubMed ID: 23158665
[TBL] [Abstract][Full Text] [Related]
33. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P].
Liu Y; Ke XY; Wang J; Wang YF; Dong F; Tian L; Wan W; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):802-806. PubMed ID: 28641639
[TBL] [Abstract][Full Text] [Related]
34. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients].
Liu XL; Yang PY; Yu XY; Chen JC; Liu XL; Bai J; Liu YM; He H; Sun JN; Fan HQ; Zhang C; Zhang Y; Su KJ; Liu CS; Tan YH; Gao SJ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):408-413. PubMed ID: 29779352
[No Abstract] [Full Text] [Related]
35. [Influence of Combination with 1q21 Amplification or-No in Patients with Newly Diagnosed MM on the Clinical Effecacy of Bortezomib-based induction chemotherapy and Long-Term Prognosis of Patients].
Gu WW; Wang JS; Mu K; Ren G
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1251-1255. PubMed ID: 32798407
[TBL] [Abstract][Full Text] [Related]
36. [Comparison of clinicopathological features and prognosis between adenocarcinoma of esophagogastric junction and adenocarcinoma of gastric antrum].
Zhu Z; Wang Y; Li F; Gao J; Han B; Wang R; Xue Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):149-155. PubMed ID: 30799537
[TBL] [Abstract][Full Text] [Related]
37. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.
Zhang BL; Zhou J; Lin QD; Liu YZ; Zhang YL; Gui RR; Song YP; Fang BJ
Artif Organs; 2019 Oct; 43(10):1028-1034. PubMed ID: 30972806
[TBL] [Abstract][Full Text] [Related]
38. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma].
Yang PY; Liu MM; Fan HQ; Yang YP; Han W; Yu XY; Yue TT; Su KJ; Guo Q; Gao SJ; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):584-588. PubMed ID: 32397022
[No Abstract] [Full Text] [Related]
39. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy and prognostic factors of induction therapy combined with autologous stem cell transplantation in 201 patients with multiple myeloma].
Jin L; Fu W; Xi H; Zhang C; Du J; He H; Jiang H; Zeng T; Fan J; Zhou L; Chang H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):14-9. PubMed ID: 26876247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
